Hong Zong

机构：First Affiliated Hospital of Zhengzhou University · ORCID：0000-0002-7731-1822

发表论文 176 篇 · 总被引 2646 次 · h-index 30

代表论文

• A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 14)
• Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer. (2025 · Journal of Clinical Oncology · 被引 9)
• First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results. (2025 · Journal of Clinical Oncology · 被引 9)
• A pooled analysis of JSKN003, a biparatopic anti-HER2 antibody conjugate (ADC), in patients with advanced HER2-overexpressing (IHC 3+) gastrointestinal tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies. (2025 · Journal of Clinical Oncology · 被引 4)
• Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor–Positive and ERBB2 -Negative Advanced Breast Cancer After Endocrine Therapy (2025 · JAMA Oncology · 被引 3)